Shots:
- BMS has partnered with Hengrui to advance 13 early-stage programs, incl. 4 Hengrui onco/hemo assets, 4 BMS immunology assets, and 5 jointly discovered & developed candidates; expected to close in Q3’26
- Hengrui will lead early clinical development, while BMS gains ex-China rights to Hengrui-originated assets & Hengrui will secure exclusive Greater China rights to BMS-originated assets, with options to co-develop & support global commercialization of select programs
- As per the deal, Hengrui will receive ~$950M, incl. $600M upfront, $175M first anniversary payment, & $175M in contingent anniversary payment in 2028, while the deal carries a potential total value of ~$15.2B through option exercises, milestone payments, & tiered ex-China royalties
Ref: PRnewswire | Image: BMS & Hengrui | Press Release
Related News: Oxford BioTherapeutics Partners with BMS to Develop Next-Generation T-cell Engagers for Solid Tumors
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
